Difference between revisions of "Pharmacia Corporation"
Mira Purska (talk | contribs) (→Affiliations) |
(PR & Lobbying) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 10: | Line 10: | ||
==People== | ==People== | ||
| − | [[Fred Hassan]] | + | * [[Fred Hassan]] (1997-2003)<ref> Schering-Plough [http://www.schering-plough.com/schering_plough/about/management_team.jsp Management Team] Accessed 26th February 2008</ref>. Hassan joined [[Schering-Plough]] in 2003 where he serves as Chairman of the Board and Chief Executive Officer. He is also President of the [[International Federation of Pharmaceutical Manufacturers Associations]] and was previously chairman of the Board of Directors of the [[Pharmaceutical Research and Manufacturers of America]] (PhRMA) and chairman of the [[HealthCare Institute of New Jersey]]. Haasan has also in the past worked for [[Wyeth]] and [[Sandoz Pharmaceuticals]] (now [[Novartis]]). |
| + | |||
| + | * [[Robert Shapiro]] | ||
[[Thomas Koestler]] Head of Regulatory Affairs | [[Thomas Koestler]] Head of Regulatory Affairs | ||
| Line 31: | Line 33: | ||
*[[Pharmacia Allergy Research Foundation]] | *[[Pharmacia Allergy Research Foundation]] | ||
*[[Arthritis Care]] upon the request from [[National Institute for Clinical Excellence]] launched a campaign for the wider prescribing of a new COX-2 inhibitor based on misleading positive results six months into a 12 month study. It did not declare that their campaign was funded by the drug manufacturers [[Pharmacia]] and [[Pfizer]] <ref>[http://www.bmj.com/cgi/content/full/bmj;326/7400/1211-a Charities and patient groups should declare interests] 31 May, 2003, BMJ</ref> | *[[Arthritis Care]] upon the request from [[National Institute for Clinical Excellence]] launched a campaign for the wider prescribing of a new COX-2 inhibitor based on misleading positive results six months into a 12 month study. It did not declare that their campaign was funded by the drug manufacturers [[Pharmacia]] and [[Pfizer]] <ref>[http://www.bmj.com/cgi/content/full/bmj;326/7400/1211-a Charities and patient groups should declare interests] 31 May, 2003, BMJ</ref> | ||
| + | |||
| + | ==PR & Lobbying== | ||
| + | In 2008, Pharmacia is listed as a past or current client of The [[Gorlin Group]]<ref>The Gorlin Group [http://www.gorlingroup.com/ Clients] Accessed 20th March 2008</ref> | ||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Pharmaceutical Industry]] | [[Category:Pharmaceutical Industry]] | ||
Latest revision as of 11:58, 20 March 2008
Pharmacia Animal Health, part of Pharmacia Corporation
History
Pharmacia was founded in 1911 in Sweden. Starting in the 1980s, the company played an active role in the process of restructuring the pharmaceutical industry by acquiring or merging with a number of companies in Sweden and abroad. Thus KabiVitrum, Leo, Ferrosan and ACO became part of the Pharmacia Group, as did the Italian-based Farmitalia Carlo Erba, acquired in 1993.
- 1995 merged with the American-based Upjohn
- 1997 Pharmacia Biotech merges with Amersham Life Science; sale of Biotech in August and merger with Amersham Life Science.
- 1998 Divestment programme in nutrition business; sale of Ortho businesses approved.
- 1999 Merger with Sugen; 20% stake acquisition in Sensus Drug Development Corp; proposed sale of the company’s sweeteners and biogums businesses; divestiture of the Stoneville Pedigreed Seed Company; sale of the alignates business: failed merger with Delta & Pine Land Company.
- 2000 European Commission confirms approval for merger with Monsanto Company: new company commences trading in April under the name Pharmacia Corp; agricultural operations of the former Monsanto Company placed into a subsidiary of Pharmacia with the name Monsanto Company; North American rights retrieved for Nicotrol; sale of the former Monsanto Nutrition and Consumer Products businesses.
- 2002 Pfizer announces acquisition of Pharmacia Corp. [1]
People
- Fred Hassan (1997-2003)[2]. Hassan joined Schering-Plough in 2003 where he serves as Chairman of the Board and Chief Executive Officer. He is also President of the International Federation of Pharmaceutical Manufacturers Associations and was previously chairman of the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA) and chairman of the HealthCare Institute of New Jersey. Haasan has also in the past worked for Wyeth and Sandoz Pharmaceuticals (now Novartis).
Thomas Koestler Head of Regulatory Affairs
Affiliations
- Ruder Finn
- Global Public Affairs Institute
- Social Market Foundation, funder
- American Academy of Neurology
- American College of Cardiology
- American Medial Women's Association
- American Society for Reproductive Medicine
- Arthritis Foundation
- Endocrine Society
- Leukemia and Lymphoma Society
- March of Dimes
- National Mental Health Association
- Oncology Nursing Society
- Society for Women's Health Research
- Pharmacia Allergy Research Foundation
- Arthritis Care upon the request from National Institute for Clinical Excellence launched a campaign for the wider prescribing of a new COX-2 inhibitor based on misleading positive results six months into a 12 month study. It did not declare that their campaign was funded by the drug manufacturers Pharmacia and Pfizer [3]
PR & Lobbying
In 2008, Pharmacia is listed as a past or current client of The Gorlin Group[4]
References
- ↑ Euromonitor
- ↑ Schering-Plough Management Team Accessed 26th February 2008
- ↑ Charities and patient groups should declare interests 31 May, 2003, BMJ
- ↑ The Gorlin Group Clients Accessed 20th March 2008
